Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

mpany implemented a one-for-ten reverse split of all outstanding shares of its common stock and a corresponding decrease in the number of shares of authorized common stock. Share and per share amounts contained herein are provided on a post-split basis.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to c
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Guidance New Launches Should Contribute ... Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced ... Quarter and Six Month Results, For the second quarter ... and a net loss of $20.1 million, or $0.60 per ...
... Aug. 7 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" ... into an arrangement agreement (the "Arrangement Agreement") dated,August ... ("Calyx"), a,wholly-owned subsidiary of Chromos, and Modatech Systems ... agreement have agreed to effect a plan,of arrangement ...
... CITY, Aug. 7 Thousands of AIDS activists,gathered today ... a key event of the XVII International AIDS Conference. ... protections,for people living with HIV and those most affected ... use drugs, and men who,have sex with men., ...
Cached Biology Technology:Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 2Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 3Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 4
(Date:4/23/2014)... researcher has shed light on how an estimated one ... outback have become reviled as pests and culled on ... and Sustainability Institute at the University of Exeter,s Penryn ... from their historic role helping to create the country,s ... , The deserts of the Australian outback are a ...
(Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
(Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3
... State University researcher has demonstrated that a variety of environmental ... animal but the next three generations of its offspring. , ... the way genes turn on and offthe epigenetic effect studied ... on in the current issue of the online journal ...
... sizes. Scientists have discovered simple rules that control leaf shape during ... able to accurately emulate leaf growth from a bud. "A ... said lead author Samantha Fox from the John Innes Centre on ... bud, not flat with a pointed tip." By creating a ...
... On March 9, the New York Academy of Sciences ... of Established Regulatory Guidance." This full-day conference will explore ... challenges for follow-on versions of complex drugs. , On ... draft guidelines for implementing the Biologics Price Competition and ...
Cached Biology News:Effects of environmental toxicants reach down through generations 2First model of how buds grow into leaves 2Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference 2
Prepared from plasminogen by activation with immobilized human uPA...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human GFR alpha-4 Affinity Purified Polyclonal Ab...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
Biology Products: